compani
execut solid fda action
olumiant/galc focu
drive perform
rais sales/ep vs street
safeti clinical/post-market pt across countri
sway fda earli june decis optim diabet payer mix
minim profit minim price concern trulic rewind
data expect less sick pt nvo trial durat galc/
elanco sale/ipo reiter ep support
dcf
rais sales/ep solid commerci execut
rais sale street driven
higher diabet sale partial off-set lower women health
rais ep vs street
higher revenu lower tax rate revis sales/ep
at/abov top-end lli rang immunolog think olumi
extens safeti databas patient year data clinical/post-
market rheumatoid arthriti ra approv countri convinc
fda approv dose despit fda advisori committe adcom
vote approv safeti concern taltz ideal posit face
competit geograph label expans ad leg growth
diabet optim payer mix counter pricing/access pressur
trulic approach leadership posit novo nordisk nvo
rate victoza rewind cv outcom data need
compet nvo ozemp out-year lli rewind evalu
patient nvo vs longer durat median
lasmiditan la tanezumab add growth sale
expect look extern growth must-win oncolog
sale/spin could add addit dri powder
financi buyer line well-posit grow revenu
target expand margin model sales/ep cagr
vs street reiter pt
ep support dcf risk includ pricing/competit pressur esp
diabet commerci execut regulatori clinic ip alimta risk
tr target
compani
olumi safeti heavili concentr use
need fda approv dose olumi treatment rheumatoid
arthriti ra order competit us market view olumi regulatori action
expect earli june fda adcom support approv dose base risk/benefit profil
despit almost unanim vote efficaci data ye dose
support approv panel vote favor safeti profil dose vote
safeti profil dose maintain stanc overal incid deep
vein thrombosi and/or pulmonari embol dvt/pe olumi per patient year
well within background rate observ ra patient although fda consid
adcom recommend final decis bind dose olumi
approv countri includ eu japan countri olumi
launch dose use major patient safeti profil consist result
clinic patient-year safeti data clinic develop
year data clinical/post-market experi support approv dose remind
olumi carri black triangl warn venou thromboembol european label
although risk note special warn precaut section expect secur
label dose label dose specif certain sub-popul
post-market studi add safeti databas continu studi dose
indic atop dermat five on-going psoriat arthriti roll-out
system lupu erythematosu sle potenti roll-out commerci olumi launch
germani japan progress well report sale qoq model
olumi sale vs street model vs street
taltz label expans add leg growth despit competit
lli taltz face competit novarti nv rate cosentyx broader label heavi free
sampl johnson johnson rate tremfya click nv read-across
taltz secur new-to-brand nbrx share market dermatolog pois
growth beyond label expans kicks-in note click taltz launch
psoriat arthriti us/germani taltz also met primari secondari endpoint
first ankylos spondyl trial coast-v mid-februari read-out remain two studi
coast-w coast-x expect model taltz sale vs street
model well street
trulic growth out-year hing rewind data
trulic continu gain share us market latest monthli trx/nrx climb
vs nvo victoza trulic post yoy growth overal
class grew trulic face rise competit nvo ozemp semaglutid
limit payer access kept share ozemp posit cv outcom better glucos
reduct weight loss click note data like erod trulic market
posit view unless trulic deliv compar better cv outcom result rewind
studi call manag comment import rewind result rewind
extrem import believ longer term us competit class
need cardiovascular outcom expect top-lin result rewind full result
follow ada meet jun also state rewind may less sick
popul compar ozemp trial see exhibit expect longer trial durat
allow trulic cv benefit fulli reflect data also note lli rewind evalu
patient nvo cv outcom studi patient vs longer
year median follow-up vs final previous outlin click nvo invest
heavili develop oral semaglutid formul oral sema broad program
includ ten trial base diabet market model expect global market grow
mid-teen compound-annual-growth-rate trulic maintain share model trulic
sale vs street
need growth trulic well jardianc basaglar off-set declin short act
insulin humalog/humulin jardianc maintain market leadership us share
nbrx share term us new therapi start jardianc command share
endocrinologist primari care physician pcp point continu growth
page
compani
view endocrinologist prescrib behavior tend lead indic pcp uptak despit
market leader think jardianc signific room growth expect
lly/bi heart failur hf pivot trial emperor-reduc emperor-preserv show
rapid signific benefit primari cv endpoint potenti data compel enough result
earli stop interim analys partner boehring ingelheim privat also plan
initi jardianc chronic kidney diseas ckd trial bullish ckd indic
base result empa-reg outcom studi jardianc show reduct risk
kidney diseas onset/progress click model jardianc allianc revenu vs
street lli biosimilar insulin glargin basaglar also expect drive diabet franchis
growth basaglar captur nbrx/trx share us market expens nvo
sanofi sni rate model basaglar sale vs street note click
sanofi biosimilar admelog expect caus eros lli humalog conting
contract strategi howev note humalog abl secur higher realiz price
due chang payer mix less government/high commerci expect similar benefit
remaind rais humalog sale vs street
model vs street
oncolog growth support io alimta verzenio dtc
oncolog verzenio abemaciclib shown earli success breast cancer market
us nbrx share approach six month launch ahead nv kisqali uptak
impress given verzenio initi gain access address breast cancer
market single-ag fulvestrant-combo howev verzenio approv use combin
aromatas inhibitor late feb ad remain market opportun hr
breast cancer accord agent current penetr address
market suggest signific room growth model verzenio sale vs street
lli alimta expect benefit robust surviv benefit seen merck buy
data click model alimta sale yoy vs street
base data see modest upsid alimta pre-u loe sale vs
street cyramza hand struggl us face competit io
agent announc cyramza trial rang bladder cancer show posit overal
surviv os trend hit statist signific evalu data determin next
step note click even os posit thought cyramza commerci prospect
bladder cancer limit sinc five market io agent us approv
indic share full data click cyramza hepatocellular carcinoma
june file cyramza intrigu
intern asset pipelin howev think oncolog area need look
bolster growth busi develop consid oncolog must-win high growth area
oncolog grow compound-annual-growth-rate per industri research
need becom better posit order sustain long-term franchis sale growth
emerg pain franchis provid anoth leg growth
lli emerg pain franchis repres fourth leg growth diabet immunolog
oncolog expect fda action lli cgrp galcanezumab galc prophylact treatment
chronic/episod migrain cm/em fda accept bla dec view galc
meaning launch opportun pain franchis rate partner nv
may pdufa date cgrp asset aimovig erenumab approv amgn/nv
like month first-mov advantag howev believ galc differenti due
strong data earli onset efficaci proportion higher percentag patient achiev
 reduct migrain think comprehens data packag
galc includ endpoint month vs amgn/nv aimovig data month provid
regul physicians/pay granular understand patient respons galc
aimovig regulatori file also base phase phase studi chronic migrain
increas regulatori risk view teva teva rate cgrp fremanezumab frema
june pdufa date approval/launch could delay due manufactur concern
final alder aldr rate plan file bla intraven cgrp eptinezumab
chronic/episod migrain exhibit compar clinic trial result four main
cgrp asset chronic/episod migrain caution alway cross-trial comparison
inher risk given trial design differ view galc differenti class
confer apr present integr analysi galc trial patient
page
compani
fail respond multipl previou prevent treatment data show
monthli dose galc effect lower monthli headach day vs placebo
cm/em patient patient fail prior prevent treatment well patient
fail multipl prior treatment think data allow posit galc
appropri follow-on treatment patient want switch ineffect therapi
model galc sale street also note galc cgrp
apart frema pursu cluster headach galc cgam cgal data
expect
acut migrain set expect receptor agonist lasmiditan la well-
posit take share approv click jan deep dive lasmiditan
collect long-term safeti data gladiat la conduct drug-drug interact drive
studi ahead nda file expect la us approv acut migrain
compar la trial result two oral cgrp exhibit allergan buy ubrogep ubro
biohaven rate rimegep rime keep mind gener caveat cross-
trial comparison view la efficaci data robust compar ubro rime liver toxic
also key safeti concern oral cgrp like ubro rime expect kol view la
safer select altern acut migrain patient cv risk factor
take triptan la sale street
final also develop anti-nerv growth factor monoclon antibodi tanezumab
collabor hold osteoarthr oa hip knee chronic low back
pain read-out first trial durat oa expect fall
remain trial oa week efficaci studi long-term safeti
studi chronic low back pain tango expect read earli
believ tanezumab significantli underappreci street offer pfe/lli novel non-opioid
asset global pain market assum data posit expect lly/pf file tanezumab
global regulatori author
oncolog could fuel elanco sale/ipo
consist previou commentari lli manag appear eager execut
oncolog lli ceo call oncolog number one target lli clinical-stag busi
develop plan remind click enter two small/early-stag deal
oncolog curevac privat deal up-front equiti invest
mileston focus rna technolog topa privat deal term
undisclos focus immun toler also focus bi-specif antibodi think
lli bd-appetit strateg financi standpoint focus early-stag asset ideal
think look tuck-in oncolog acquisit reason valuat could potenti
provid one commerci product well sever intrigu asset early-to-mid
stage pipelin right asset becom avail think plenti dri powder
mid-siz acquisit cash equival net debt/ebitda ratio
think could pursu acquisit larg without requir signific
sharehold dilut assum focus primarili opportun rang
analysi strateg altern busi proceed schedul
expect share conclus review earn call juli note click note
think divest elanco busi make strateg sens sharehold financi
think total consider elanco busi like base combin
dcf rel valu analysi although bloomberg report other valu elanco
accord bloomberg attract interest elanco busi privat equiti firm
includ bain capit carlyl group view announc lli strateg
review conclus potenti spin/sal elanco busi signific catalyst share
page
compani
exhibit comparison nvo studi ozemp lli rewind studi trulic
cv outcom
durat follow-up
clinic evid cvd
subclin evid cvd
within day prior random
clinic evid cvd
within day prior random
mean durat diabet
rate non-fatal myocardi infarct
rate non-fatal stroke
strh research new england journal medicin nov diabet obes metabol may compani report
page
compani
exhibit cross-trial efficaci comparison inject cgrp inhibitor
mechan action
measur primari
reduct monthli migrain
measur primari
reduct monthli migrain
measur primari
reduct monthli migrain
page
mechan action
measur endpoint
patient migrain headach
pain free two hour
patient mb free two
measur endpoint
patient migrain headach
pain free two hour
patient mb free two
compani
exhibit cross-trial efficaci comparison emerg acut migrain treatment
page
compani
one-off guidanc updat sigilon deal
rate well
page
compani
sale
sale
page
compani
page
compani
exhibit estim strh vs consensu
page
compani
page
compani
 alzheim partner azn
page
compani
exhibit incom statement
sale
page
compani
exhibit consolid balanc sheet
equival
st borrow current portion lt debt
accumul comprehens loss
common stock treasuri
total liabil sharehold equiti
page
compani
exhibit statement
chang defer tax
net oper
restrict cash releas acquisit
dispos prop equip
addit asset
reduct invest
addit invest
net invest
purchas common stock
chang st borrow cpltd
addit long-term debt
reduct long-term debt
net financ
effect exchang rate
cash/equival begin period
cash/equival end period
page
compani
lilli lead research-bas biopharmaceut compani focus drug discoveri
clinic develop manufactur commerci pharmaceut product human
anim diseas gener sale yoy gener
us ex-u market human medicin busi includ core franchis
neurosci diabet women oncolog cardiovascular contribut
 total sale global leader diabet arena new product
trulic basaglar collabor asset jardianc tradjenta lli oncolog franchis
compris inhibitor verzenio abemaciclib alimta cyramza portrazza lartruvo
also place stake ground establish immunolog franchis
launch taltz olumi lli fourth leg emerg growth target pain market
three late-stag asset galcanezumab lasmiditan tanezumab enter one
best new product cycl year histori new product launch trulic jardianc
rate buy base attract low-teen earn growth mid-singl
digit volum driven sale growth commit expand oper margin tight
cost manag new product cycl unfold
model assum doubl diabet franchis level
jardianc basaglar trulic offset declin establish product
humalog humulin expect jardianc take materi share market older
gener therapi owe cardiovascular-benefit estim share shift
older gener therapi jardianc equat sale conting discount rebat
put upward pressur out-year estim also expect doubl
oncolog franchis base support verzenio alimta cyramza
portrazza lartruvo verzenio third-to-market inhibitor segment data
junip studi nsclc ad anoth leg growth alimta expect benefit combo use
keytruda first-lin non-smal cell lung cancer nsclc alimta alreadi substanti
presenc non-squam nsclc market model assum maintain us exclus
alimta
immunolog taltz olumi baricitinib expect contribut sale
continu progress olumi clinic commerci despit delay us
rheumatoid arthriti file think olumi long-term growth benefit expand asset
commerci reach much possibl geograph eu/japan label expans
atop dermat system lupu erythematosu psoriat arthriti taltz posit captur
mid-teen percentag psoriasi treat patient popul next five year lastli lli
emerg pain franchis repres fourth leg growth differenti late-stag asset
significantli derisk galcanezumab lasmiditan tanezumab galcanezumab robust efficaci
placebo-lik safeti posit take materi share cgrp market lasmiditan first-in-class
molecul offer cardiovascular safeti advantag acut migrain standard-
oper leverag margin expans central thesi compani contain fix
cost grow revenu base next five year lli streamlin oper
improv cost structur posit achiev opex goal sale
valuat risk
pt assum trade ep reflect premium current
forward group averag forward price-to-earnings multipl think premium group averag
multipl justifi given lli diversifi volume-driven sale growth mid-singl digit sale
compound-annual-growth-rate oper leverag oper margin goe price
target support discount cash flow dcf intrins valu per share
page
compani
risk thesi revolv around price commerci execut regulatori clinic risk
face upcom patent expir ciali alimta well recent
expir patent strattera competit pressur trulic semaglutid humalog
biosimilar insulin lispro expect off-set four launch verzenio
galcanezumab olumi baricitinib lasmiditan
compani mention note
alder biopharmaceut inc aldr rate
amgen inc rate
ltd rate
johnson johnson rate
novarti ag nv rate
novo nordisk a/ nvo rate
sanofi sni rate
teva pharmaceut industri limit teva rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
